

28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(-Delta Delta C(T)) Method. *Methods* 2001; **25**(4): 402-408. doi: 10.1006/meth.2001.1262.

29. Atari-Hajipirloo S, Nikanfar S, Heydari A, Kheradmand F. Imatinib and its combination with 2, 5-dimethyl-celecoxib induces apoptosis of human HT-29 colorectal cancer cells. *Res Pharm Sci* 2017; **12**(1): 67-73 . doi: 10.4103/1735-5362.199049.

30. Vallböhmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindbjerg J, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. *Int J Oncol* 2007;**31**(2): 413-418. PMID:17611699.

31. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshe S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. *Clin Cancer Res* 2000; **6**(4): 1322-1327.

32. Murakawa M, Aoyama T, Miyagi Y, et al. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. *Oncol Lett* 2017;**14**(2):1505-1511. doi:10.3892/ol.2017.6295.

33. Yoshida Y, Ogura K, Hiratsuka A, Inoue N, Yamada T, Kojima D, et al. 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose Escalation Method. *Anticancer Res* 2015; **35**(9): 4881-4887.

34. Bertino EM, Fekri Saab T, Fernandez S, et al. A phase II study of modulated-capecitabine and docetaxel in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer* 2012;**79**(1):27-32. doi: [10.1016/j.lungcan.2012.09.013](https://doi.org/10.1016/j.lungcan.2012.09.013).

35. Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. *World J Gastroenterol* 2018;**24**(34):3834-3848. doi: 10.3748/wjg.v24.i34.3834.